Results 141 to 150 of about 197,589 (314)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis

, 2018
Chenfei Zhou,1,* Xiaojing Feng,2,* Fei Yuan,3 Jun Ji,4 Min Shi,1 Yingyan Yu,4 Zhenggang Zhu,1,4 Jun Zhang1 1Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Department ...
Yuan F, Shi M, Zhu Z, Zhang J, Zhou C, Feng X, Ji J, Yu Y   +7 more
core  

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

, 2014
ABSTR ACT: Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30 % of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with
Adam M. Brufsky
core   +1 more source

HER2-Low Breast Cancer: Current Landscape and Future Prospects

, 2023
Yelena Shirman, Shlomit Lubovsky, Ayelet Shai Division of Oncology, Rambam Health Care Campus, Haifa, IsraelCorrespondence: Ayelet Shai, Division of Oncology, Rambam Health Care Campus, HaAliya HaShniya St 8, PO Box 9602, Haifa, 3109601, Israel, Tel +972-
Shai A, Lubovsky S, Shirman Y
core  

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib

, 2023
Baha’ Sharaf, Hala Abu-Fares, Faris Tamimi, Suhaib Al-Sawajneh, Osama Salama, Rand Daoud, Abdulrahman Alhajahjeh, Sawsan Al-Lababidi, Hikmat Abdel-Razeq Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanCorrespondence: Hikmat ...
Tamimi F, Alhajahjeh A, Daoud R, Al-Lababidi S, Salama O, Abdel-Razeq H, Al-Sawajneh S, Sharaf B, Abu-Fares H   +8 more
core  

Advances in Chitosan Nanoparticles: A Comprehensive Review of Properties, Synthesis, Characterization, Multidisciplinary Applications, and Future Perspectives

Journal of Applied Polymer Science, EarlyView.
This review highlights the synthesis of chitosan nanoparticles from natural sources, the thorough characterization of them, and use of microscopic and spectroscopic methods. It emphasizes that it has some indispensable properties such as being non‐toxic, antimicrobial, and capable of controlled drug release.
Mariam Sohail Mansoor, Nayab Raza, Furqana Bibi, Madiha Mumtaz, Asif Abbas, Farasat Haider, Basit Ali   +6 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

[Role of HER2 in NSCLC].

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015
The therapeutic strategy of non-small cell lung cancer (NSCLC) is dramatically changed with the introduction of molecular targeted drugs in the last years, resulting in a series of results in histologic and molecular level. The discovery of epidermal growth factor receptor (EGFR) mutation, Kirsten rat sarcoma (KRAS) viral oncogene mutation and ...
Kun ZHANG, Hong WANG
openaire   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source